Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.

MLA

Ebert, B., et al. “Ketobemidone plus (RS)-3-Dimethylamino-1,1-Diphenylbut-1-Ene (A29) Is More Potent at NMDA Receptors than Ketobemidone Alone: Evidence for A29 as a Non-Competitive NMDA Receptor Antagonist.” Pharmacology & Toxicology, vol. 82, no. 3, Mar. 1998, pp. 157–60. EBSCOhost, https://doi.org/10.1111/j.1600-0773.1998.tb01417.x.

APA

Ebert, B., Thorkildsen, C., & Andersen, S. (1998). Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist. Pharmacology & Toxicology, 82(3), 157–160. https://doi.org/10.1111/j.1600-0773.1998.tb01417.x

Chicago

Ebert, B, C Thorkildsen, and S Andersen. 1998. “Ketobemidone plus (RS)-3-Dimethylamino-1,1-Diphenylbut-1-Ene (A29) Is More Potent at NMDA Receptors than Ketobemidone Alone: Evidence for A29 as a Non-Competitive NMDA Receptor Antagonist.” Pharmacology & Toxicology 82 (3): 157–60. doi:10.1111/j.1600-0773.1998.tb01417.x.